European genetics study of hearing impairment in patients with cancer during childhood treated with cisplatin.

Completed

• Conditions: hearing impairment; ototoxicity; 10027667; 10027656

• Registration Number: NL-OMON41760
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

Treated with cisplatin
Diagnosed before the age of 18 years
End-of treatment pure tone audiograms
No radiotherapy administered to head/neck
Normal pre-treatment audiogram

Exclusion Criteria

No informed consent
Pre-existing known hearing impairment

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Difference in genetic profile between patients with and without ototoxicity.<br /><br>Audiograms. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Age.<br /><br>Treatment regimen.<br /><br>Co-treatment with diuretics and aminoglycosides.<br /><br>Renal function. </p><br>